Foundry Partners LLC Increases Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Foundry Partners LLC raised its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% during the third quarter, Holdings Channel.com reports. The fund owned 15,781 shares of the specialty pharmaceutical company’s stock after purchasing an additional 509 shares during the quarter. Foundry Partners LLC’s holdings in Collegium Pharmaceutical were worth $610,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Caxton Associates LP bought a new position in Collegium Pharmaceutical in the 1st quarter worth $1,730,000. Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Collegium Pharmaceutical by 194.5% in the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after buying an additional 72,874 shares during the period. Assenagon Asset Management S.A. boosted its position in Collegium Pharmaceutical by 411.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after acquiring an additional 291,286 shares in the last quarter. Finally, BOKF NA purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth approximately $490,000.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $29.96 on Friday. The business has a fifty day moving average price of $35.84 and a 200-day moving average price of $34.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $966.21 million, a PE ratio of 12.91 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 1-year low of $25.16 and a 1-year high of $42.29.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on COLL shares. Truist Financial raised their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.